Boca Raton, Florida, November 22 (ots/PRNewswire)
announces the presentation of data from two research projects at the
11th Annual CTOS (Connective Tissue Oncology Society) Meeting, which
took place in Florida, USA, from November 19-21, 2005.
The first presentation highlighted data from a retrospective study
conducted in tumour samples from patients of soft tissue sarcoma
treated with Yondelis(R) in Europe, while the second presentation
examined the results of a preclinical study of Yondelis in cell
lines explanted from chemo-naïve patients.
Yondelis(R) - two oral presentations
1. "A deficient homologous recombination DNA repair appears to
cluster sarcoma patients sensitive to Yondelis(R) (ET-743,
trabectedin)" was a retrospective study conducted in tumour samples
from patients with sarcoma treated with Yondelis in Europe that seeks
to provide a greater understanding of sensitivity/resistance to
Yondelis by examining the molecular signature of the tumours. The
results indicate that patients with a defined pattern of tumour DNA
repair efficiency have a higher probability of better survival. They
are expected to have a major impact on the optimisation of Yondelis
in studies in solid tumours that are sensitive to Yondelis.
2. "Mutated P53 correlates with extreme sensitivity to Yondelis(R)
in low passaged cell lines explanted from chemonaïve sarcoma
patients" showed molecular evidence that correlates extreme in vitro
sensitivity to Yondelis(R) with mutation of the p53 gene. Such
evidence, in contrast with the pattern applicable to classical
chemotherapeutic agents, provides a useful tool for patients'
improvement strategies in prospective studies.
Commenting on the CTOS presentations, José Jimeno, VP of
Scientific Development at PharmaMar, said, "The data presented at the
CTOS meeting demonstrate the selective and targeted effects of
Yondelis and reinforce the significant novelty of this marine-derived
compound. Should these preliminary findings be confirmed by further
studies, they may constitute a relevant tool to improve patients'
treatment with Yondelis and to enhance the drug profile in
prospective clinical trials."
PharmaMar is the world's leading biopharmaceutical company in
advancing cancer care through the discovery and development of
innovative marine-derived medicines. PharmaMar's clinical portfolio
currently includes: Yondelis(R) (co-developed with Johnson & Johnson
Pharmaceutical Research & Development) in Phase III clinical trials;
it is also designated Orphan Drug for Soft Tissue Sarcomas and for
ovarian cancer by the European Commission (E.C.) and by the Food &
Drug Administration (FDA). It also features Aplidin(R), in Phase II,
designated Orphan Drug for acute lymphoblastic leukaemia and for
multiple myeloma; as well as Kahalalide F in Phase II, and ES-285,
Zalypsis(R) and PM02734 in Phase I clinical trials.
PharmaMar, based in Madrid, Spain, is a subsidiary of the Zeltia
Group, a leading European biotechnology and consumer chemical group
(Spanish stock exchange, ZEL).
This press release is also available in the News section on
PharmaMar's web site: http://www.pharmamar.com/en/press
For more information, contact:
Zeltia Corporate Communication
Zeltia Capital Markets Operations
ots Originaltext: PharmaMar
Im Internet recherchierbar: http://www.presseportal.ch
Media: Lola Casals, PharmaMar Communication, tel. +34-91-846-6000.
Teresa Garcia, Zeltia Corporate Communication, tel. +34-91-444-4500.
Investors: Catherine Moukheibir, Zeltia Capital Markets Operations,